Advanced green chemistry, HPLC method development and validation: Integrating stability indicating, quality by design (QbD), in ferulic acid and its application in NLCs-based nanoformulation

被引:0
|
作者
Meshram, Preeti [1 ]
Ranpise, Nisharani [1 ]
机构
[1] Savitribai Phule Pune Univ, Sinhgad Coll Pharm, Dept Pharmaceut, Pune 411007, Maharastra, India
关键词
Ferulic acid; Nanostructured lipid carrier; Robustness; Validation; Stress degradation; PHASE; METHANOL; HYDROCHLORIDE; OPTIMIZATION; DEGRADATION; SEPARATION;
D O I
10.1080/22297928.2024.2428933
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The biopharmaceutical class IV classification of ferulic acid (FA) restricts its use. FA-loaded nanostructured lipid carriers (NLCs) were developed to overcome these issues. It is difficult to quantify the lowest concentration of the drug by another method. The proposed method can determine the lowest concentration in nanoformulation and biological fluids including urine, plasma, blood, and tissues. The proposed method utilizes a novel QbD-based approach, which reduces trial-and-error production costs and market recalls and maintains a risk-benefit ratio, due to the use of optimized inputs and outputs. The use of a green chemistry approach (Acetonitrile: water) can detect even small degradants. The degradant found under stress conditions ensures the safety, efficacy, quality, and stability of the formulations. The optimized method showed linearity with r2 0.9988 in a range of 10-60 mu g/ml at a retention time of 3.690 +/- 0.01 at a run time of 8 minutes. The recovery rate of FA was found in a range of 95.28 +/- 0.54% to 97.98 +/- 0.48%. The obtained %RSD precision was (0.01-0.21%) for intra-day, whereas inter-day precision was (0.09-0.51%). The lowest concentrations to be detected and quantified were 2.4 and 7.3 mu g/ml. The AQbD approach built an optimized method providing significant output. The found stress degradation recovery was (6.2 +/- 0.98% to 33.46 +/- 0.22%), thus from the recovered degradant concentrations, further work for safety, efficacy, quality, and stability can proceed. Thus RP-HPLC adheres to ICH guidelines and is found to be straightforward, precise, and sensitive for routine quality control analysis of FA in bulk and nanoformulations, plasma, tissues, and other biological fluids.
引用
收藏
页码:909 / 934
页数:26
相关论文
共 25 条
  • [21] Stability-indicating RP-HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach
    Subramanian, Velusamy B.
    Katari, Naresh Kumar
    Dongala, Thirupathi
    Jonnalagadda, Sreekantha B.
    BIOMEDICAL CHROMATOGRAPHY, 2020, 34 (01)
  • [22] Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies
    Chen, Guanyu
    Svirskis, Darren
    Wen, Jingyuan
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2015, 67 (11) : 1528 - 1536
  • [23] DoE-assisted development and validation of a stability-indicating HPLC-DAD method for simultaneous determination of five cannabinoids in Cannabis sativa L. based on analytical quality by design (AQbD) concept
    de Souza, Maira Ribeiro
    Koetz, Mariana
    Limberger, Renata Pereira
    Henriques, Amelia Teresinha
    PHYTOCHEMICAL ANALYSIS, 2022, 33 (07) : 999 - 1017
  • [24] Application of a Quality by Design-based approach in development and validation of an RP-HPLC method for simultaneous estimation of methotrexate and mangiferin in dual drug-loaded liposomes
    Adin, Syeda Nashvia
    Gupta, Isha
    Aqil, Mohd.
    Mujeeb, Mohd.
    Najmi, Abul Kalam
    BIOMEDICAL CHROMATOGRAPHY, 2023, 37 (08)
  • [25] Dual Organic Modifier, Solid Core Technology and Quality by Design Based Tripartite Synergistic Model for Development and Validation of Stability Indicating Method by Reverse Phase-High Performance Liquid Chromatography for Assay and Impurities of Etoricoxib Tablets
    Kolla, S. B.
    Vallabhaneni, M. R.
    Puttagunta, S. B.
    Chakka, V. V. S. M.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 (03) : 683 - 702